Publication | Open Access

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

Hematological MalignancyLymphoid NeoplasiaComplement Dependent CytotoxicityMedicineImmunologyHematologyPathologyCll CellsImmunotherapyOncologyCancer Research